Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Digoxin-prescribing. Mostly good news.

M Weintraub, F E Karch, J P Morgan

    JAMA
    |August 3, 1979
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Measurement of Reactor Antineutrino Oscillation at SNO.

    Physical review letters·2025
    Same author

    Measurement of the Positive Muon Anomalous Magnetic Moment to 127 ppb.

    Physical review letters·2025
    Same author

    A first vocal repertoire characterization of long-finned pilot whales (<i>Globicephala melas</i>) in the Mediterranean Sea: a machine learning approach.

    Royal Society open science·2024
    Same author

    Measurement of the Positive Muon Anomalous Magnetic Moment to 0.20 ppm.

    Physical review letters·2023
    Same author

    Confined placental mosaicism: placental size and function evaluated on magnetic resonance imaging.

    Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2023
    Same author

    Detection of low numbers of bacterial cells in a pharmaceutical drug product using Raman spectroscopy and PLS-DA multivariate analysis.

    The Analyst·2022
    Same journal

    WHO Issues Guidelines for Treating Ebola and Marburg Viruses.

    JAMA·2026
    Same journal

    FDA Approves Additional Naloxone Nasal Spray for Opioid Overdose.

    JAMA·2026
    Same journal

    HIV May Hide in More Cells Than Previously Thought-Here's What That Could Mean for a Cure.

    JAMA·2026
    Same journal

    US Dietary Supplement Use Increasing, Especially in Older Adults.

    JAMA·2026
    Same journal

    Heat Stress From Climate Change Surges Globally.

    JAMA·2026
    Same journal

    Strength Training Linked With Lower Cardiovascular Disease Risk in Women.

    JAMA·2026
    See all related articles

    Physicians adjusted digoxin doses for patient age, renal disease, and atrial fibrillation, indicating good prescribing practices. However, less than 40% of prescriptions favored the brand-name digoxin (Lanoxin) despite concerns about generic bioavailability.

    Area of Science:

    • Cardiology
    • Pharmacology
    • Family Medicine

    Background:

    • Digoxin is a critical medication for managing heart conditions like atrial fibrillation.
    • Concerns persist regarding the bioavailability and therapeutic equivalence of generic digoxin formulations compared to the innovator brand, Lanoxin.
    • Optimizing digoxin prescribing practices is essential for patient safety and treatment efficacy.

    Purpose of the Study:

    • To evaluate digoxin prescribing patterns in a large family medicine practice.
    • To assess adherence to recommended dose adjustments based on patient factors.
    • To determine the proportion of digoxin prescriptions written for the brand-name product (Lanoxin) versus generics.

    Main Methods:

    • Retrospective analysis of 47,000 prescriptions from a family medicine practice.

    Related Experiment Videos

  • Identification of 254 patients receiving 511 digoxin prescriptions.
  • Examination of dose adjustments in relation to age, renal disease, and atrial fibrillation status.

    • Main Results:

    • Dose reductions were observed in 16% of patients over 64 years and 33% with renal disease.
    • A 39% increase in dose was noted for patients with atrial fibrillation, aligning with clinical guidelines.
    • Less than 40% of digoxin prescriptions were for the innovator brand (Lanoxin), despite bioavailability concerns.

    Conclusions:

    • Digoxin prescribing demonstrated appropriate dose adjustments for key patient demographics and conditions.
    • The low utilization of brand-name Lanoxin warrants further investigation, particularly concerning generic digoxin bioavailability.
    • Ensuring optimal digoxin therapy requires continued attention to formulation choice and patient-specific dosing.